How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,793 results for

("National Institute of Allergy and Infectious Disease" OR NIAID) AND (statistics OR statistical OR data OR demography OR demographics OR demographic)

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Outcomes of early NIH-funded investigators: Experience of the National Institute of Allergy and Infectious Diseases. (PubMed)

Outcomes of early NIH-funded investigators: Experience of the National Institute of Allergy and Infectious Diseases. Survival of junior scientists in academic biomedical research is difficult in today's highly competitive funding climate. National Institute of Health (NIH) data on first-time R01 grantees indicate the rate at which early investigators drop out from a NIH-supported research career is most rapid 4 to 5 years from the first R01 award. The factors associated with a high risk (...) of dropping out, and whether these factors impact all junior investigators equally, are unclear. We identified a cohort of 1,496 investigators who received their first R01-equivalent (R01-e) awards from the National Institute of Allergy and Infectious Diseases between 2003 and 2010, and studied all their subsequent NIH grant applications through 2016. Ultimately, 57% of the cohort were successful in obtaining new R01-e funding, despite highly competitive conditions. Among those investigators who failed

Full Text available with Trip Pro

2018 PLoS ONE

2. Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. (PubMed)

of the first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods beginning in infancy.Prompted by these findings, along with 25 professional organizations, federal agencies, and patient advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum guidelines to specifically address (...) Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. Food allergy is an important public health problem because it affects children and adults, can be severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development

Full Text available with Trip Pro

2017 Journal of Allergy and Clinical Immunology

3. Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. (PubMed)

of the first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods beginning in infancy.Prompted by these findings, along with 25 professional organizations, federal agencies, and patient advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum guidelines to specifically address (...) Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. Food allergy is an important public health problem because it affects children and adults, can be severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development

Full Text available with Trip Pro

2016 Asthma & Immunology

4. HIV and aging: demographic change in the Asia-Pacific region (PubMed)

HIV and aging: demographic change in the Asia-Pacific region 28267699 2018 02 27 2018 11 13 1944-7884 74 5 2017 04 15 Journal of acquired immune deficiency syndromes (1999) J. Acquir. Immune Defic. Syndr. HIV and Aging: Demographic Change in the Asia-Pacific Region. e146-e148 10.1097/QAI.0000000000001258 Puhr Rainer R *The Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia†YRGCARE Medical Centre, Chennai, India‡The University of Health Sciences with the National Center for HIV (...) , Thailand. Kumarasamy Nagalingeswaran N Ly Penh Sun PS Ng Oon Tek OT Van Nguyen Kinh K Merati Tuti Parwati TP Pham Thuy Thanh TT Lee Man Po MP Choi Jun Yong JY Ross Jeremy L JL Law Matthew G MG eng U01 AI069907 AI NIAID NIH HHS United States Letter Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States J Acquir Immune Defic Syndr 100892005 1525-4135 0 Anti-Retroviral Agents IM X Adolescent Adult Age Distribution Aged Aged, 80 and over Anti-Retroviral Agents

Full Text available with Trip Pro

2017 Journal of acquired immune deficiency syndromes (1999)

5. Evaluation of National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria for the diagnosis of anaphylaxis in emergency department patients. (PubMed)

Evaluation of National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria for the diagnosis of anaphylaxis in emergency department patients. Diagnostic criteria were proposed at the Second Symposium on the Definition and Management of Anaphylaxis convened by the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN). Validation is needed before these criteria can be widely adapted into clinical practice.Our (...) aim was to retrospectively assess the diagnostic accuracy of the NIAID/FAAN criteria for the diagnosis of anaphylaxis in emergency department (ED) patients.A retrospective cohort study of ED patients presenting from April to October 2008 was conducted. Patients given a diagnosis of an allergic reaction or anaphylaxis and a subset of patients with related diagnoses were included. Electronic medical records were reviewed and data were abstracted to determine whether the NIAID/FAAN criteria were met

2011 Journal of Allergy and Clinical Immunology

6. P-values and reproductive health: what can clinical researchers learn from the American Statistical Association? (PubMed)

United States T32 AI007358 AI NIAID NIH HHS United States R01 ES009718 ES NIEHS NIH HHS United States R01 ES022955 ES NIEHS NIH HHS United States R01 ES024749 ES NIEHS NIH HHS United States Editorial Research Support, N.I.H., Extramural 2016 09 22 England Hum Reprod 8701199 0268-1161 IM J Urol. 2017 Aug;198(2):238-240 29370618 Biomedical Research standards Data Interpretation, Statistical Humans Models, Statistical Probability Reproductive Health Statistics as Topic standards P-values biostatistics (...) confidence interval data interpretation statistical significance 2016 07 09 2016 07 01 2016 07 08 2016 9 25 6 0 2018 1 25 6 0 2016 9 25 6 0 ppublish 27664212 dew192 10.1093/humrep/dew192 PMC5088632 Eur J Epidemiol. 2016 May;31(5):443-4 27272951 J Gen Intern Med. 2014 Jul;29(7):1060-4 24452418 Nature. 2014 Feb 13;506(7487):150-2 24522584 Int J Cardiol. 2014 Dec 20;177(3):1089-90 25449519 Epidemiology. 1990 Jan;1(1):43-6 2081237 Eur J Epidemiol. 2016 Apr;31(4):337-50 27209009

Full Text available with Trip Pro

2016 Human reproduction (Oxford, England)

7. NIAID Centralized Sequencing Protocol

of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03206099 Recruitment Status : Recruiting First Posted : July 2, 2017 Last Update Posted : March 8, 2019 See Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Information provided by (Responsible (...) Party): National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ) Study Details Study Description Go to Brief Summary: Background: Genetic testing called sequencing helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and some cause differences like blue

2017 Clinical Trials

8. Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop (PubMed)

of the bone marrow, skin, gastrointestinal tract, brain, lung and heart. To explore the potential use of these therapies in the treatment of victims after acute radiation exposure, the National Institute of Allergy and Infectious Diseases co-sponsored an international workshop in July, 2015 in Paris, France with the Institut de Radioprotection et de Sûreté Nucléaire. The workshop included discussions of data available from testing in preclinical models of radiation injury to different organs, logistics (...) Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop In recent years, there has been increasing concern over the possibility of a radiological or nuclear incident occurring somewhere in the world. Intelligence agencies frequently report that terrorist groups and rogue nations are seeking to obtain radiological or nuclear weapons of mass destruction. In addition, there exists the real possibility that safety of nuclear power reactors could

Full Text available with Trip Pro

2017 Radiation research

9. Understanding the Pathophysiology and Challenges of Development of Medical Countermeasures for Radiation-Induced Vascular/Endothelial Cell Injuries: Report of a NIAID Workshop, August 20, 2015 (PubMed)

processes and progression, as well as the optimum approaches to develop medical countermeasures to mitigate radiation vascular injury. To address this issue, the Radiation and Nuclear Countermeasures Program of the National Institute of Allergy and Infectious Diseases (NIAID) organized a one-day workshop to examine the current state of the science in radiation-induced vascular injuries and organ dysfunction, the natural history of the pathophysiology and the product development maturity of potential (...) Understanding the Pathophysiology and Challenges of Development of Medical Countermeasures for Radiation-Induced Vascular/Endothelial Cell Injuries: Report of a NIAID Workshop, August 20, 2015 After the events of September 11, 2001, a decade of research on the development of medical countermeasures (MCMs) to treat victims of a radiological incident has yielded two FDA-approved agents to mitigate acute radiation syndrome. These licensed agents specifically target the mitigation of radiation

Full Text available with Trip Pro

2016 Radiation research

10. Assessing the public health impact of HIV interventions: the critical role of demographics (PubMed)

Mathematics, University of Washington, Seattle, WA ‡School of Mathematical and Statistical Sciences, Arizona State University, Tempe, AZ §Department of Mathematics, King Abdulaziz University, Jeddah, Saudi Arabia ‖CHU Sainte-Justine Research Centre, University of Montreal, Montreal, Quebec, Canada. Kuang Yang Y Mâsse Benoît R BR eng UM1 AI068615 AI NIAID NIH HHS United States 5 U01AI068615-03 AI NIAID NIH HHS United States Letter Research Support, N.I.H., Extramural Comment United States J Acquir Immune (...) Assessing the public health impact of HIV interventions: the critical role of demographics 24828270 2014 07 03 2018 12 02 1944-7884 66 2 2014 Jun 01 Journal of acquired immune deficiency syndromes (1999) J. Acquir. Immune Defic. Syndr. Assessing the Public Health impact of HIV interventions: the critical role of demographics. e60-2 10.1097/QAI.0000000000000133 Dimitrov Dobromir D *Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA †Department of Applied

Full Text available with Trip Pro

2014 Journal of acquired immune deficiency syndromes (1999)

11. Statistical methods for the assessment of EQAPOL proficiency testing: ELISpot, Luminex, and Flow Cytometry (PubMed)

Statistical methods for the assessment of EQAPOL proficiency testing: ELISpot, Luminex, and Flow Cytometry In September 2011 Duke University was awarded a contract to develop the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) External Quality Assurance Program Oversight Laboratory (EQAPOL). Through EQAPOL, proficiency testing programs are administered for Interferon-γ (IFN-γ) Enzyme-linked immunosorbent spot (ELISpot), Intracellular Cytokine (...) Staining Flow Cytometry (ICS) and Luminex-based cytokine assays. One of the charges of the EQAPOL program was to apply statistical methods to determine overall site performance. We utilized various statistical methods for each program to find the most appropriate for assessing laboratory performance using the consensus average as the target value. Accuracy ranges were calculated based on Wald-type confidence intervals, exact Poisson confidence intervals, or via simulations. Given the nature

Full Text available with Trip Pro

2014 Journal of immunological methods

12. NIAID Clinical Center Genomics Opportunity Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02417766 Recruitment Status : Completed First Posted : April 16, 2015 Last Update Posted : January 31, 2019 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Information provided by (Responsible Party): National Institutes of Health (...) Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ) Study Details Study Description Go to Brief Summary: Background: - There are many types of immune disorders. These range from rare immune deficiencies to allergies to autoimmune disease like rheumatoid arthritis. Genes are the instructions our body uses to work and develop. A new technology called whole exome sequencing may help find the cause of these disorders. Whole exome sequencing is a way to look at many genes

2015 Clinical Trials

13. Birth cohorts in asthma and allergic diseases: Report of a NIAID/NHLBI/MeDALL joint workshop. (PubMed)

Birth cohorts in asthma and allergic diseases: Report of a NIAID/NHLBI/MeDALL joint workshop. Population-based birth cohorts on asthma and allergies increasingly provide new insights into the development and natural history of the diseases. More than 130 birth cohorts focusing on asthma and allergy have been initiated in the last 30 years. A National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Mechanisms of the Development of Allergy (MeDALL (...) ; Framework Programme 7 of the European Commission) joint workshop was held in Bethesda, Maryland, on September 11-12, 2012, with 3 objectives: (1) documenting the knowledge that asthma/allergy birth cohorts have provided, (2) identifying the knowledge gaps and inconsistencies, and (3) developing strategies for moving forward, including potential new study designs and the harmonization of existing asthma birth cohort data. The meeting was organized around the presentations of 5 distinct workgroups: (1

Full Text available with Trip Pro

2014 Journal of Allergy and Clinical Immunology

14. Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data (PubMed)

Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data 29150057 2018 07 17 2018 11 13 1873-2518 35 48 Pt A 2017 12 04 Vaccine Vaccine Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. 6518-6528 S0264-410X(17)30101-9 10.1016/j.vaccine.2017.01.040 Schlaudecker Elizabeth P EP Cincinnati Children's Hospital Medical Center (...) of South Carolina, Columbia, SC, USA. Khalil Asma A Fetal Medicine Unit, St George's Hospital, University of London, UK. Mousa Hatem H Fetal Medicine Unit, University Hospital of Leicester, UK. Nesin Mirjana M Office of Clinical Research Resources, NIAID/NIH, Rockville, MD, USA. Nisar Muhammad Imran MI Aga Khan University, Department of Pediatrics and Child Health, Karachi, Pakistan. Pool Vitali V Sanofi Pasteur, Swiftwater, PA, USA. Spiegel Hans M L HML Kelly Government Solutions, Contractor to DAIDS

Full Text available with Trip Pro

2017 Vaccine

15. Neonatal encephalopathy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data (PubMed)

Neonatal encephalopathy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data 29150055 2018 07 17 2018 11 13 1873-2518 35 48 Pt A 2017 12 04 Vaccine Vaccine Neonatal encephalopathy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data. 6501-6505 S0264-410X(17)30108-1 10.1016/j.vaccine.2017.01.045 Sell Erick E Children's Hospital of Eastern Ontario, Canada. Electronic address (...) ), Contractor to DAIDS/NIAID/NIH, Rockville, United States. Sawlwin Daphne D Therapeutic Area Lead, Vaccines, Safety Risk Management, Australian QPPVCSL Limited Melbourne, Australia. Šubelj Maja M National Institute of Public Health, Ljubljana, Slovenia. Tikhonov Ilia I Sanofi Pasteur, United States. Mohammad Khorshid K University of Calgary, Section of Neonatology, Department of Pediatrics, Foothills Medical Centre, Canada. Kochhar Sonali S Global Healthcare Consulting, Delhi, India; Erasmus University

Full Text available with Trip Pro

2017 Vaccine

16. Congenital microcephaly: Case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation (PubMed)

Government Solutions (KGS), Contractor to DAIDS/NIAID/NIH, Rockville, United States. Nesin Mirjana M National Institutes of Health/National Institute of Allergy and Infectious Disease, United States. Tagbo Beckie N BN Institute of Child Health & Department of Paediatrics, University of Nigeria Teaching Hospital, Enugu, Nigeria. Shrestha Anju A Sanofi Pasteur, Global Pharmacovigilance, Sanofi Pasteur, United States. Cutland Clare L CL Medical Research Council: Respiratory and Meningeal Pathogens Research (...) Congenital microcephaly: Case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation 29150052 2018 07 17 2018 11 13 1873-2518 35 48 Pt A 2017 12 04 Vaccine Vaccine Congenital microcephaly: Case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation. 6472-6482 S0264-410X(17)30107-X 10.1016/j.vaccine.2017.01.044 DeSilva Malini M Health Partners Institute for Education

Full Text available with Trip Pro

2017 Vaccine

17. It’s 10 pm; do you know where your data are?: Data Provenance, Curation and Storage (PubMed)

It’s 10 pm; do you know where your data are?: Data Provenance, Curation and Storage 28495991 2018 11 13 1524-4571 120 10 2017 May 12 Circulation research Circ. Res. It's 10 pm; Do You Know Where Your Data Are? Data Provenance, Curation, and Storage. 1551-1554 10.1161/CIRCRESAHA.116.310424 Anderson Mark E ME From the Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD (M.E.A., S.C.R.); and Department of Physiology and the Program in Cellular and Molecular (...) United States R01 HL070250 HL NHLBI NIH HHS United States R01 HL071140 HL NHLBI NIH HHS United States U19 AI088791 AI NIAID NIH HHS United States Journal Article United States Circ Res 0047103 0009-7330 Circ Res. 2017 Jun 23;121(1):e1 28642326 2017 5 13 6 0 2017 5 13 6 0 2017 5 13 6 0 ppublish 28495991 CIRCRESAHA.116.310424 10.1161/CIRCRESAHA.116.310424 PMC5465863 NIHMS862758 Nature. 2016 Jun 08;534(7606):173-5 27279195

Full Text available with Trip Pro

2017 Circulation Research

18. Generating robust and informative nonclinical <i>in vitro</i> and <i>in vivo</i> bacterial infection model efficacy data to support translation to humans. (PubMed)

Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans. In June 2017, The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, organized a workshop entitled "Pharmacokinetics-Pharmacodynamics (PK/PD) for Development of Therapeutics against Bacterial Pathogens". The aims were to discuss details of various PK/PD models and identify sound practices (...) efficacy models that provide valuable and complementary information for dose selection and translation from the laboratory to human. It is crucial that studies be designed, conducted and interpreted appropriately. For antibacterial PK/PD, extensive published data and expertise are available. These have been leveraged to develop recommendations, identify common pitfalls and describe the applications, strengths and limitations of various nonclinical infection models and translational approaches. Despite

2019 Antimicrobial Agents and Chemotherapy

19. <i>In-situ</i> validation of the endothelial cell receptor GRP78 in a case of rhinocerebral mucormycosis -Letter to the Editor- (New-Data Letter). (PubMed)

In-situ validation of the endothelial cell receptor GRP78 in a case of rhinocerebral mucormycosis -Letter to the Editor- (New-Data Letter). 29483124 2019 03 11 1098-6596 62 5 2018 05 Antimicrobial agents and chemotherapy Antimicrob. Agents Chemother. In Situ Validation of the Endothelial Cell Receptor GRP78 in a Case of Rhinocerebral Mucormycosis. e00172-18 10.1128/AAC.00172-18 Shumilov Evgenii E Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG (...) ), Göttingen, Germany ibrahim@labiomed.org ramani@med.uni-goettingen.de. Department of Pathology, University Medicine Göttingen, Göttingen, Germany. eng R01 AI063503 AI NIAID NIH HHS United States Letter Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2018 04 26 United States Antimicrob Agents Chemother 0315061 0066-4804 GRP78 endothelium invasion glucose-regulated protein mucormycosis 2018 2 28 6 0 2018 2 28 6 0 2018 2 28 6 0 epublish 29483124 AAC.00172-18 10.1128/AAC.00172-18

Full Text available with Trip Pro

2018 Antimicrobial Agents and Chemotherapy

20. Use of External Quality Control Material for HIV-1 RNA Testing To Assess the Comparability of Data Generated in Separate Laboratories and the Stability of HIV-1 RNA in Samples after Prolonged Storage (PubMed)

Use of External Quality Control Material for HIV-1 RNA Testing To Assess the Comparability of Data Generated in Separate Laboratories and the Stability of HIV-1 RNA in Samples after Prolonged Storage The National Institute of Allergy and Infectious Diseases (NIAID) AIDS Clinical Trials Group (ACTG) stores specimens from its clinical trials in a biorepository and permits the use of these specimens for nonprotocol exploratory studies, once the studies for the original protocol are concluded. We (...) sought to assess the comparability of the data generated from real-time HIV-1 RNA testing during two clinical trials with the data generated from the retesting of different aliquots of the same samples after years of storage at -80°C. Overall, there was 92% agreement in the data generated for 1,570 paired samples (kappa statistic = 0.757; 95% confidence interval [CI], 0.716 to 0.797), where samples were tested in one laboratory using the microwell plate (MWP) version of the Roche HIV-1 Monitor test

Full Text available with Trip Pro

2018 Journal of clinical microbiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>